Latest News
Oxford BioTherapeutics and Boehringer Ingelheim Partnership Advances Second Oncology Drug Candidate into the Clinic
Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, today announced that it has received another milestone payment from Boehringer Ingelheim (BI) for the progress of a second oncology drug candidate (BI 765049), discovered during the first phase of the partnership, into the clinic. In addition to OBT’s … Continued
Oxford BioTherapeutics establishes research collaboration with global cell therapy leader, Kite
Oxford BioTherapeutics Ltd., a clinical stage oncology company with a pipeline of immuno-oncology (IO) and antibody-drug conjugate (ADC)-based therapies and Kite, a Gilead Company, have announced that they have entered into a research collaboration to evaluate five novel targets for a number of hematologic and solid tumor indications. Through this collaboration, OBT will validate five … Continued
Oxford BioTherapeutics Announces Second Oncology Drug Candidate Selected to Advance
Oxford BioTherapeutics (“OBT”) a clinical stage oncology company with a pipeline of immuno-oncology and antibody drug conjugate-based therapies, announced that Boehringer Ingelheim (“BI”) has selected a second asset to advance into formal IND enabling studies. The asset discovery was enabled by OBT’s proprietary OGAP® target discovery platform. It is one of several assets that have … Continued
Oxford BioTherapeutics Initiates U.S. Phase I Clinical Trial
Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company developing antibody-based immuno-oncology therapies, has announced the initiation of the dose-escalation portion of its U.S. Phase I program for OBT076, a CD205 targeting antibody-drug conjugate (ADC), in patients with advanced solid tumours. Dose-escalation is the first part of the Phase I program that includes two U.S. … Continued
2018 Nobel Prize in Medicine Awarded to Cancer Immuno-Oncology Researchers
Two scientists, who initially discovered how to harness the body’s immune system to fight cancer, have been awarded the 2018 Nobel Prize in Physiology or Medicine by the Nobel Assembly at Karolinska Institutet. The groundbreaking work of Professor James Allison, of the US, and Professor Tasuku Honjo, of Japan, has paved the way for a … Continued